Clinical trials: Cancer Disease Progression
Lung Caner
The Shengjing Lung Cancer Cohort (SJ-LCC) Study on Risk Factors for Disease Development and Progression
Modifiable risk factors, including smoking, alcohol consumption, and diet, play critical roles in cancer progression and patient prognosis.
- Trial name
- SJ-LCC (NCT07779005)
- Where
- China
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Shengjing Hospital
Glioma, Brain Neoplasms
3D-ASL and TDD-MRI for True Progression and Pseudoprogression After Glioma Surgery
Background: Differentiating true progression (TP) from pseudoprogression (PsP) after glioma surgery remains a major clinical challenge because conventional magnetic resonance imaging (MRI) often cannot reliably distinguish these…
- Trial name
- ASL-TDD (NCT07687277)
- Testing
- Multiparametric MRI (3D-ASL and TDD-MRI)
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Lanzhou University Second Hospital
Fear of Cancer Progression
A Brief Psychological Intervention for Carer Fear of Cancer Progression
This study aims to evaluate the feasibility and acceptability of the Conquer Fear Carer Brief, a three-session psychological intervention targeting fear of cancer progression among caregivers of patients with metastatic prostate…
- Trial name
- NCT07752992
- Testing
- Conquer Fear Carer Brief
- Where
- Denmark
- Volunteers
- 14 people
- Sponsor
- University of Aarhus
Metastatic Breast Cancer
Everolimus trIal for Advanced prememopausaL Breast Cancer Patients
Everolimus has been approved to be effective when used with exemestane after progression on non-steroidal aromatase inhibitors in postmenopausal women based on the BOLERO-2 clinical trial.
- Trial name
- MIRACLE (NCT02313051)
- Testing
- Everolimus, Goserelin, Letrozole
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese Academy of Medical Sciences
Non-small Cell Lung Cancer
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Researchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C.
- Trial name
- NCT07554339
- Testing
- Calderasib, Durvalumab
- Where
- 107 sites in United States, Argentina and 16 more
- Volunteers
- 310 people
- Sponsor
- Merck Sharp & Dohme LLC
Epithelial Ovarian Cancer, High-grade Serous Ovarian Carcinoma
Chromosomal Instability in Ovarian Cancer
Chromosomal instability (CIN) refers to the ongoing genomic change, which involves the amplification or deletion of chromosome copy number or structure.
- Conditions
- Epithelial Ovarian Cancer, High-grade Serous Ovarian Carcinoma, Chromosomal Instability, Somatic Copy Number Distortion
- Trial name
- NCT05310357
- Testing
- Testing for chromosomal instability (CIN)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Lei Li
Melanoma
Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
This is a phase 2, open-label, single-arm, multicenter clinical trial designed to evaluate the efficacy and safety of talimogene laherparepvec in combination with pembrolizumab following disease progression on prior…
- Trial name
- NCT04068181
- Testing
- Talimogene laherparepvec, Pembrolizumab
- Where
- 46 sites in United States, Australia and 9 more
- Volunteers
- 72 people
- Sponsor
- Amgen
GIST
Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)
The purpose of this study is to evaluate the antitumor activity of pazopanib in patients with metastatic and/or locally advanced unresectable Gastrointestinal Stromal Tumors (GIST) resistant to imatinib and sunitinib.
- Trial name
- PAZOGIST (NCT01323400)
- Testing
- Pazopanib, Best supportive care
- Where
- 13 sites in France
- Volunteers
- 81 people
- Sponsor
- Centre Leon Berard
Ovarian Cancer, Fallopian Tube Cancer
Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer
Chemoresponse assays (lab test) measure the effect that chemotherapy treatment has on a patient's cancer cells in the lab. This test has shown success in a retrospective study in predicting how an individual patient's tumor will…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
- Trial name
- NCT00288275
- Where
- 36 sites in United States
- Volunteers
- 256 people
- Sponsor
- Precision Therapeutics
Barrett's Esophagus
Preliminary Longitudinal Validation of Biomarkers Predictive of Barrett's Esophagus
Barrett's esophagus can progress to esophageal cancer, but it doesn't always. Current treatment is frequent surveillance via upper endoscopy with multiple biopsies to look for changes (dysplasia).
- Trial name
- NCT00844077
- Where
- 6 sites in United States, Canada
- Volunteers
- 255 people
- Sponsor
- University of Michigan
Graft-Versus-Host Disease, Hematological Malignancies
Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens
The present project is a multicenter phase II trail aiming at comparing which of the two postgrafting immunosuppressive regimens proposed in this study will be best suited to prevent graft-versus-host disease (GVDH).
- Trial name
- NCT01428973
- Testing
- Mycophenolate mofetil, Sirolimus
- Where
- 13 sites in Belgium
- Volunteers
- 200 people
- Sponsor
- University of Liege
Advanced Cancer, Olanzapine
Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
This study aims to assess the impact of adding olanzapine to nutritional advice and standard anti-tumor therapy on the survival and safety of patients with locally advanced, unresectable or metastatic gastric cancer, esophageal…
- Conditions
- Advanced Cancer, Olanzapine, Progression Free Survival
- Trial name
- NCT06338683
- Testing
- Olanzapine 2.5 MG, Standard anti-tumor treatment, Nutritional advice
- Where
- China
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Qinghai Red Cross Hospital
Anaplastic Thyroid Cancer
Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy
This pilot phase 2 study evaluates the effectiveness and safety of the Rechallenge concept in patients with BRAF-positive anaplastic thyroid cancer after progression on anti-BRAF therapy.
- Trial name
- NCT06362694
- Testing
- Dabrafenib + Trametinib
- Where
- Russia
- Volunteers
- 10 people
- Sponsor
- Saint Petersburg State University, Russia
Gastric Cancer
Antiangiogenic Factors in Gastric Cancer
Endogenous antiangiogenic factors are related with gastric cancer progression.
- Trial name
- NCT00735566
- Where
- South Korea
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- National Cancer Center, Korea
Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II
Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer
The goal of this clinical trial is to test a new combination treatment for locally advanced rectal cancer (cancer in the lower or middle part of the rectum that has not spread to distant organs).
- Conditions
- Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II, Rectal Cancer Stage III
- Trial name
- NCT07397442
- Testing
- Short-Course Radiotherapy Combined with Chemotherapy and Immunotherapy
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Beijing Friendship Hospital
Lung Cancer
Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Metastatic Lung Cancer and Metastatic Melanoma Receiving Post-progression Immune Checkpoint Inhibitor Therapy
This research study is studying cryoablation (a treatment to kill cancer cells with extreme cold) combined with continued treatment with current immune checkpoint inhibitor as a possible treatment for lung cancer.
- Trial name
- NCT03290677
- Testing
- Cryoablation, Biopsy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Endometrial Neoplasms, Neoplasm Recurrence, Local
Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of cadonilimab in combination with paclitaxel, cisplatin, and radiation therapy for the treatment of locally recurrent and oligometastatic endometrial…
- Conditions
- Endometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis
- Trial name
- NCT06532539
- Testing
- Paclitaxel and Cisplatin, Cadonilimab, Radiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shandong Cancer Hospital and Institute
Carcinoid Heart Disease, Carcinoid Syndrome
Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy
Randomised trial to assess progression of carcinoid heart disease in patients treated with Lutathera therapy compared to best supportive care.
- Conditions
- Carcinoid Heart Disease, Carcinoid Syndrome, Carcinoid Tumor
- Trial name
- CHARRT (NCT04039516)
- Testing
- Lutathera
- Volunteers
- 20 people
- Sponsor
- King's College Hospital NHS Trust
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.
This study will evaluate the efficacy and safety of a first-line regimen of Avastin and Xelox (Xeloda + Eloxatin) followed by Avastin and Tarceva, in patients with metastatic colorectal cancer.
- Trial name
- NCT01135498
- Testing
- bevacizumab [Avastin], eloxatin, capecitabine [Xeloda]
- Where
- 12 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC
Bev improves the efficacy of first-line chemotherapy in unresectable mCRC. In the phase III TRIBE trial upfront FOLFOXIRI plus bev provided a significant advantage in terms of PFS and RR compared to FOLFIRI plus bev.
- Trial name
- TRIBE2 (NCT02339116)
- Testing
- fluoruracil, Oxaliplatin, Irinotecan
- Where
- Italy
- Volunteers
- 654 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.